Predict your next investment

Corporation
chiesi.com

See what CB Insights has to offer

Investments

4

Portfolio Exits

1

Partners & Customers

10

About Chiesi Farmaceutici

Chiesi Farmaceutici is an international research-focused pharmaceutical company that researches, develops, and markets drugs in the respiratory therapeutics, neonatology, specialist medicine, and rare diseases areas.

Chiesi Farmaceutici Headquarter Location

Via Palermo, 26/A

Parma, 43122,

Italy

+39 0521 2791

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Chiesi Farmaceutici News

BRIEF—Post hoc analysis of Chiesi’s Kengreal

Jan 25, 2022

The US subsidiary of Italian drugmaker Chiesi Farmaceutici has announced that a post hoc analysis of the CHAMPION PHOENIX clinical trial that evaluated treatment of Kengreal (cangrelor) in patients undergoing percutaneous coronary intervention (PCI) was published in Circulation: Cardiovascular Interventions. The analysis found that the majority of ischemic events occurred early in PCI, and Kengreal treatment significantly reduced these events in the first two hours post-randomization compared to clopidogrel, the standard of care. “These results demonstrate the importance of potent platelet inhibition during this critical window of treatment,” said Martin Marciniak, vice president and head of US medical affairs at Chiesi. “We are thankful for the contributions of everyone who participated in this valuable analysis, and we’re committed to supporting advancements in interventional cardiology to improve care for cardiac patients,” he added.

Chiesi Farmaceutici Investments

4 Investments

Chiesi Farmaceutici has made 4 investments. Their latest investment was in Cyclica as part of their Series B on June 6, 2020.

CBI Logo

Chiesi Farmaceutici Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/24/2020

Series B

Cyclica

$17M

Yes

4

9/25/2018

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

7/10/2013

Project Finance

Subscribe to see more

$99M

Subscribe to see more

10

7/10/2013

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/24/2020

9/25/2018

7/10/2013

7/10/2013

Round

Series B

Series B - II

Project Finance

Series B

Company

Cyclica

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$17M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

10

10

10

Chiesi Farmaceutici Portfolio Exits

1 Portfolio Exit

Chiesi Farmaceutici has 1 portfolio exit. Their latest portfolio exit was uniQure on February 05, 2014.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/5/2014

IPO

$99M

1

Date

2/5/2014

Exit

IPO

Companies

Valuation

$99M

Acquirer

Sources

1

Chiesi Farmaceutici Acquisitions

4 Acquisitions

Chiesi Farmaceutici acquired 4 companies. Their latest acquisition was Smart Pharma on September 17, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/17/2020

Seed / Angel

$99M

$0.4M

Acquired

2

11/21/2016

Debt

Subscribe to see more

$99M

$99M

Subscribe to see more

10

2/4/2014

Other Venture Capital

Subscribe to see more

$99M

$99M

Subscribe to see more

10

8/26/2013

Grant

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

9/17/2020

11/21/2016

2/4/2014

8/26/2013

Investment Stage

Seed / Angel

Debt

Other Venture Capital

Grant

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Total Funding

$0.4M

$99M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

Chiesi Farmaceutici Partners & Customers

10 Partners and customers

Chiesi Farmaceutici has 10 strategic partners and customers. Chiesi Farmaceutici recently partnered with Kaia Health on November 11, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

11/30/2020

Client

Kaia Health

United States

Kaia Health teams with Chiesi Group to commercialise COPD app in Europe

Konstantin Mehl , Kaia Health founder and president , said : `` Our strategic partnership with Chiesi , a growing global company with an established European commercial presence , brings a wealth of experience in navigating the respiratory health landscape in Europe , while expanding patient access to evidence-based , digital physical pulmonary rehabilitation . ''

6

9/1/2020

Vendor

JAGGAER

United States

Chiesi Group and JAGGAER Drive Strategic Supplier Management and Procurement Excellence

`` JAGGAER has been a terrific partner , helping us exceed B Corp certification standards and build transparency , efficiency , and agility in our approach with defined processes , clear ownership and accountability , management over exceptions , structured information sharing , and more . ''

2

7/6/2020

Licensor

Bioasis Technologies

United States

Bioasis and Chiesi announce licensing agreement - BioCT

Bioasis Technologies and Chiesi announce licensing agreement .

1

6/29/2020

Licensor

Bioasis Technologies

United States

Subscribe to see more

Subscribe to see more

10

12/10/2018

Partner

Centogene

Germany

Subscribe to see more

Subscribe to see more

10

Date

11/30/2020

9/1/2020

7/6/2020

6/29/2020

12/10/2018

Type

Client

Vendor

Licensor

Licensor

Partner

Business Partner

Kaia Health

JAGGAER

Bioasis Technologies

Bioasis Technologies

Centogene

Country

United States

United States

United States

United States

Germany

News Snippet

Kaia Health teams with Chiesi Group to commercialise COPD app in Europe

Konstantin Mehl , Kaia Health founder and president , said : `` Our strategic partnership with Chiesi , a growing global company with an established European commercial presence , brings a wealth of experience in navigating the respiratory health landscape in Europe , while expanding patient access to evidence-based , digital physical pulmonary rehabilitation . ''

Chiesi Group and JAGGAER Drive Strategic Supplier Management and Procurement Excellence

`` JAGGAER has been a terrific partner , helping us exceed B Corp certification standards and build transparency , efficiency , and agility in our approach with defined processes , clear ownership and accountability , management over exceptions , structured information sharing , and more . ''

Bioasis and Chiesi announce licensing agreement - BioCT

Bioasis Technologies and Chiesi announce licensing agreement .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

6

2

1

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.